Buprenorphine xr over 100 mg
Products billed under this code include Sublocade.
Payment limit per Greater than 100 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Sublocade.
Payment limit per Greater than 100 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Sublocade | Indivior Inc. | 12496-0300-01 | 1 | $2,060.132 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $2,060.132 | −$8.023 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted September 17, 2026 |
| 3Q26 | $2,068.155 | +$71.598 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted September 15, 2026 |
| 2Q26 | $1,996.557 | −$1.976 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted September 15, 2026 |
| 1Q26 | $1,998.533 | −$17.89 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted September 15, 2026 |
| 4Q25 | $2,016.423 | +$39.871 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted September 8, 2026 |
| 3Q25 | $1,976.552 | +$51.321 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted March 10, 2026 |
| 2Q25 | $1,925.231 | −$6.581 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted March 10, 2026 |
| 1Q25 | $1,931.812 | −$11.246 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted December 19, 2025 |
| 4Q24 | $1,943.058 | −$18.501 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted June 11, 2025 |
| 3Q24 | $1,961.559 | +$86.657 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted June 11, 2025 |
| 2Q24 | $1,874.902 | −$12.211 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted March 11, 2025 |
| 1Q24 | $1,887.113 | +$0.136 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted December 19, 2024 |
| 4Q23 | $1,886.977 | +$0.61 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted October 10, 2024 |
| 3Q23 | $1,886.367 | +$92.52 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted June 5, 2024 |
| 2Q23 | $1,793.847 | −$31.986 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted February 23, 2024 |
| 1Q23 | $1,825.833 | −$16.343 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted December 6, 2023 |
| 4Q22 | $1,842.176 | −$16.434 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted June 22, 2023 |
| 3Q22 | $1,858.61 | +$77.301 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted June 9, 2023 |
| 2Q22 | $1,781.309 | −$5.723 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted December 14, 2022 |
| 1Q22 | $1,787.032 | −$9.766 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted June 8, 2022 |
| 4Q21 | $1,796.798 | −$19.853 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted June 2, 2022 |
| 3Q21 | $1,816.651 | +$80.111 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted June 2, 2022 |
| 2Q21 | $1,736.54 | −$0.717 | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted March 1, 2022 |
| 1Q21 | $1,737.257 | – | Greater than 100 MG | Buprenorphine xr over 100 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.